Bloomberg Politics, March 10, 2017. While Gottlieb has focused on easing regulations, he “understands the agency and has some respect for it,” Diana Zuckerman, NCHR president, said in an interview before the news that Gottlieb is the leading candidate.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Drug Companies Are Exploiting This Law to Keep Prices High
Attn, March 8, 2017. Pharmaceutical companies are exploiting a Food and Drug Administration (FDA) policy to undermine competitors and maintain monopolies on their products.
Read More »2017 Foremother and Health Policy Hero Awards Luncheon Invitation
February 21, 2017. Reserve your ticket! We hope you will join us at our annual Awards Luncheon: Foremother and Health Policy Hero Awards. Monday May 15, 2017, at noon at the historic Mayflower Hotel. Champagne reception for patrons and sponsors at 11:30.
Read More »Amid Flurry of New Cancer Drugs, How Many Offer Real Benefits?
Kaiser Health News, February 9, 2017. For every cancer patient who wins the lottery, there are many others who get little to no benefit from the latest drugs.
Read More »Trump’s Proposed Changes Gut FDA While Targeting Drug Prices
Legal Reader, February 2, 2017. In a study published on the JAMA Network, Dr. Zuckerman and her co-author, Tracy Rupp, looked at certain new – and expensive – cancer drugs. They found that many of these drugs failed to improve patient quality of life or extend patient life.
Read More »